Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma Leukemia (2015) 29, 2429-2431; doi:10.1038/leu.2015.274
Integration of novel agents into first-line therapy for newly diagnosed multiple myeloma (MM) patients who are eligible to receive an autologous stem cell transplantation (ASCT) has led to unprecedented rates of high-quality responses. 1 Based on the results of several phase III trials, 2-5 a three-drug induction regimen including bortezomib and dexamethasone (VD) is currently considered the standard of care in preparation for ASCT. The European Medicines Agency recently approved the combination of bortezomib with thalidomide and dexamethasone (VTD) for this use. However, alternative triplet therapies built on the backbone of VD, including VD plus either lenalidomide (VRD) or cyclophosphamide (VCD), are commonly given in routine practice, although their use is not supported by results of phase III studies. Our involvement over the past years in the design and coordination of two consecutive large phase III trials incorporating either VTD or VCD as induction therapy for ASCT-eligible MM patients, prompted us to perform a retrospective case-matched analysis aimed to evaluate the efficacy and toxicity of these two popular regimens in a representative sample size. For this purpose, 236 patients who were randomly assigned to the VTD arm of the GIMEMA-MMY-3006 study (registered with ClinicalTrials.gov, number NCT01134484), were compared with an equal number of pair mates who were enrolled in the European Myeloma Network (EMN)-02 study (registered with ClinicalTrials.gov, number NCT01208766). By study design, these latter patients were planned to be treated with VCD induction and subsequent cyclophosphamide to collect peripheral blood stem cells before randomization to receive either ASCT upfront or bortezomibmelphalan-prednisone followed by ASCT at the time of relapse. Case matching was performed with respect to the following patient characteristics at baseline: age (± 2 years), international staging system (ISS) stage (1 vs 2 vs 3) and presence or absence of t(4;14) ( ⩾ 10 vs o 10%) and/or del(17p) ( ⩾ 20 vs o20%) detected by fluorescence in situ hybridization analysis of CD138+ bone marrow plasma cells. The two groups were also comparable with respect to additional prognostic variables. In both studies, induction treatment with either VTD, as reported elsewhere, 2 or VCD consisted of three 21-day cycles. In VCD, the dosing schedules of VD were the same than in VTD (for example, bortezomib, 1.3 mg/m 2 intravenously (i.v.), twice-weekly, and dexamethasone, 320 mg per cycle) with the addition of cyclophosphamide, 500 mg/m 2 i.v. on days 1 and 8. Responses evaluated by investigators after the three cycles of induction therapy or the last cycle actually received in case of early treatment discontinuation were centrally reassessed by the study coordinating team according to the IMWG criteria 6 and analyzed on an intention-totreat basis. Overall, the rates of complete response (CR), very good partial response (VGPR) or higher and at least partial response were significantly higher with VTD vs VCD (Table 1 ). In particular, VTD increased by more than three times the rate of CR in comparison with VCD (19 vs 6%, P o0.001), a gain retained across Accepted article preview online 7 October 2015; advance online publication, 3 November 2015 subgroups of patients with ISS stage 2+3 (20 vs 4%, Po 0.001) and high-risk cytogenetics, as defined by the presence of t(4;14) and/ or del(17p) (23 vs 8%, P = 0.030) ( Table 1) . By the opposite, the probability to achieve less than partial response was threefold lower with VTD vs VCD; in particular, no patient assigned to VTD experienced disease progression during induction therapy vs 3% in the VCD-treated group (P = 0.015). Adverse events (AEs) were graded by use of NCI-CTCAE version 3.0 and were grade 3-4 in 27% of patients in the VTD group and 26% of those in VCD. Of the most common grade 3-4 AEs recorded during induction therapy and listed in Table 2 , peripheral neuropathy (PN) 7 and skin rash occurred more frequently with VTD compared with VCD (7 vs 2%, P = 0.009, and 8 vs 1%, P o 0.001, respectively). By the opposite, VCD was associated with a higher probability of severe anemia (7 vs 0%, P = 0.003), neutropenia (8 vs 2%, P o0.001) and thrombocytopenia (4 vs o1%, P = 0.006) than VTD. Overall, the probability to discontinue induction therapy and to go off-study due to any of the reasons listed in Table 2 was 4% in both treatment groups.
Patients assigned to VTD or VCD received 95% and 96% of the planned dose of bortezomib, respectively.
Comparisons between published studies of VCD induction therapy are difficult owing to the limited sample size of patients enrolled in most of them, heterogeneities in patient characteristics and differences in treatment outlines. [8] [9] [10] [11] [12] [13] In particular, major treatment differences across the studies included dosing, route and schedule of bortezomib administration (from 1.3 to 1.5 mg/m 2 either i.v. or subcutaneously, twice-weekly or once-weekly), dosing of cyclophosphamide (between 300 and 500 mg/m 2 /once a week for 2, 3 or 4 weeks per each 21-day or 28-day cycle, corresponding to a total dose per cycle between 900 and 1500 mg/m 2 , either i.v. or orally), dosing of dexamethasone (from 160 to 480 mg per cycle), and the number of planned cycles (generally, in the 3-4 range). Despite these differences, the rate of CR after 3-4 cycles reported in most of these studies was in a close range, between 3 and 8%, 8,10,13 while VGPR or higher was observed in 16-41% of patients. 10, 13 Notably, in the phase II EVOLUTION study aimed at evaluating eight cycles of induction therapy with either VCD or VRD or VRD plus cyclophosphamide, the best response observed after a median of six cycles of VCD among patients younger than 66 years was 10% CR and 24% VGPR or better. The small number of patients enrolled in the VCD arm of this study precludes any possible conclusion about the optimal number of cycles to be given in preparation for ASCT. Although cross trial comparisons are inadequate, the rates of response reported in the studies mentioned above are consistent with those found in our casematched analysis. Results of a large phase III study aimed at demonstrating the non-inferiority of VCD compared with bortezomib-doxorubicin-dexamethasone (PAD) were recently published. 13 The 8 and 38% rates of CR and ⩾ VGPR seen among 251 patients who were randomly assigned to receive three cycles of VCD comprising VD at the same dosing planned in the EMN-02 study and cyclophosphamide at 900 mg/m 2 on day 1 are almost superimposable to our data. Differently, another group who treated two small cohorts of patients with different dosing schedules of bortezomib and weekly cyclophosphamide administered in a continuous manner reported that the probability to achieve at least VGPR after four cycles of VCD was 60%, albeit the CR rate was unsatisfactory low, at 3%. 8, 9 In our analysis, VCD was more frequently associated with severe hematological toxicity than VTD which, by the opposite, induced more often severe PN compared with VCD. Differently, the rate of grade ⩾3 PN reported in two studies of VCD incorporating standard-dose bortezomib given i.v. twice-weekly was 7 and 9%. 8, 10 It is important to highlight that in the GIMEMA-MMY-3006 study, complete resolution of grade 2 or higher PN occurred in 88% of VTD-treated patients, whereas 94% improved to at least grade 1. 7 As a result, the probability to discontinue induction therapy and not proceed throughout the subsequent treatment phases including ASCT was the same in both the same in both VTD-and VCD-treated groups. Highly active novel agent-based treatments incorporating first or second generation proteasome inhibitors combined with an immunomodulatory drug and, eventually, the addition of a monoclonal antibody targeting antigens expressed on the surface of myeloma cells support the current treatment approach to MM, which is aimed at maximizing the depth of response and minimizing the burden of tumor cells, particularly in early treatment phases. Given the possible coexistence of multiple clones with different genotypic and phenotypic characteristics, even at the onset of the disease, it is possible that the combination of multiple drugs with different mechanisms of action might inhibit clonal evolution, although this hypothesis needs to be backed by confirmatory clinical studies. 14 In addition, a growing body of evidence suggests that improvements in the depth of response are consistently associated with better outcomes across all phases of MM and regardless of the use of less or more intensive treatments. 15 In particular, attainment of high-quality responses to induction therapy before ASCT is an early predictor of prolonged progression-free survival after ASCT. Therefore, the choice of the most effective induction regimen to be used in preparation for high-dose melphalan is of primary importance for ASCT-eligible MM patients and should be carefully balanced with toxicity. Results of our analysis, as well as of other studies aimed at exploring, although not in a head-to-head manner, the role of VCD induction therapy, support the activity of this latter regimen which, however, is likely to be inferior compared with that of a three-drug regimen incorporating a proteasome inhibitor and an immunomodulatory drug, like VTD. In our study, VTD effected a threefold or higher increase in the CR rate compared to VCD and this gain was retained across subgroups of patients at high-risk, such as those with advanced ISS stage or an unfavorable cytogenetic profile. Importantly, VTD was not associated with a higher probability of any grade 3-4 AE in comparison with VCD. These data, if confirmed by the results of a phase III study conducted by the Intergroup Francophone du Myelome and aimed at prospectively comparing VTD with VCD induction therapy, might support the preferential use of a more expensive, but more active, regimen like VTD rather than VCD in preparation for ASCT in newly diagnosed MM patients.
